why choose us

Clinical Trials Search

Showing 11,500 of 132,656 result(s)
European Aortic Data Collection Project

Status: Completed

Condition: Complex Abdominal Aortic Aneurysm

Interventions: Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneur

Date: 2023-05-31

A Phase 1;2 Study of Personalized PSMA Radiopharmaceutical Therapy

Status: NOT_YET_RECRUITING

Condition: Cancer

Interventions: Personalized 177Lu-PSMA-I&T injected activity

Date: 2023-05-31

Shockwave Lithotripsy (SWL) Versus SWL and Oral Dissolution Therapy (ODT) For Paediatrics Radiolucent Renal Stone

Status: COMPLETED

Condition: Pediatric Kidney Disease

Interventions: Shockwave Lithotripsy (SWL) For Paediatrics Radiolucent Renal Stone

Date: 2023-05-31

rTMS in Older Adults With MCI and AUD

Status: NOT_YET_RECRUITING

Condition: Alcohol Use Disorder

Interventions: Participants in this group will receive 10 sessions of iTBS-rTMS per day, 5 days per week for one week (50 sessions total)

Date: 2023-05-31

Cerebral Monitoring Using Pulsatile Near Infrared Spectroscopy in Neonates

Status: Completed

Condition: Neonatal Disease

Interventions: No intervention

Date: 2023-05-31

Kisspeptin Administration Subcutaneously to Patients With IHH

Status: Completed

Condition: Hypogonadotropic Hypogonadism

Interventions: SC administration of kisspeptin for two weeks (pulsatile, every 60-240 minutes)

Date: 2023-05-31

Effect of ECPP on Recurrent Bile Duct Stones

Status: Completed

Condition: Sphincterotomy, Endoscopic

Interventions: Stones are taken by cutting the papillary sphincter

Date: 2023-05-31

Study of MAR001 in Adults With Metabolic Dysfunction

Status: NOT_YET_RECRUITING

Condition: Hypertriglyceridemia

Interventions: Subcutaneous injection

Date: 2023-05-31

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed;Refractory Multiple Myeloma

Status: NOT_YET_RECRUITING

Condition: Refractory Multiple Myeloma

Interventions:

Participants will receive Iberdomide (Iber) therapy orally (PO) in capsules as follows:

  • Combination therapy: Cycles 1 to 8: 1 mg per day

    Date: 2023-05-31